Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a
NCT ID: NCT00199732
Last Updated: 2013-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
19 participants
OBSERVATIONAL
2004-12-31
2009-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Intra lymphocyte cccDNA could be a new marker of HBV eradication after treatment.
The major interest of this marker is that it can be measured by a simple blood test instead of a liver biopsy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta
NCT00117533
Study of Telbivudine in Chronic Hepatitis B
NCT00970216
Efficacy Study of Telbivudine in Chronic Hepatitis B Patients
NCT01958229
A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment
NCT05550519
Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies
NCT00142298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\- Viral kinetics:Before inclusions, at D0, then monthly till the end of treatment and follow-up: Evolution of quantitative viraemia in serum Evolution of quantitative viraemia in circulating lymphocytes Evolution of quantitative viraemia in total blood
\- Studying viral genotypes
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients AgHbs+ and AgHbe+ or AgHbe-, and B viral DNA \>104 copies/ml PCR COBAS MONITOR
* Patients treated with adefovir dipivoxil and peg interferon alpha 2a
* Chronic liver disease consistent with chronic hepatitis B infection on a biopsy obtained within the past 24 months
* Naïve patients or patients having a relapse or a therapeutic failure after monotherapy lamivudine or interferon, or bitherapy interferon alpha-lamivudine
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
University Hospital, Limoges
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Véronique Loustaud-Ratti, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Limoges
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Hépato-gastroentérologie
Limoges, , France
Service de Médecine Interne
Limoges, , France
Service de Virologie
Limoges, , France
Service des Maladies Infectieuses et Tropicales
Limoges, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I04002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.